evoke semaglutide trial EVOKE/EVOKE+ AAN 2026 - Results from

Available at: (Accessed April 5, 2023)

We believe that it is wrong to mislead doctors and patients by omitting common side effects

Jin SM, Kim JH, Min KW, et al

GLP-1 drugs like Semaglutide demonstrated significant weight loss benefits for patients with a BMI over 40, making them a preferred option for managing high-risk obesity cases

No guesswork, no syringe graduation errors, no approximate measurements

The isoelectric point of semaglutide sits around pH 5.4, and degradation accelerates significantly between pH 4.5 and 5.5, which means that any formulation changes caused by temperature exposure can compound the problem by shifting the solution toward less stable conditions